Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with
the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for
patients with documented hormone refractory prostate cancer who have not had any prior
therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly
over two 6 week courses separated by a 2 week rest period.